CO2017005498A2 - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia - Google Patents

Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Info

Publication number
CO2017005498A2
CO2017005498A2 CONC2017/0005498A CO2017005498A CO2017005498A2 CO 2017005498 A2 CO2017005498 A2 CO 2017005498A2 CO 2017005498 A CO2017005498 A CO 2017005498A CO 2017005498 A2 CO2017005498 A2 CO 2017005498A2
Authority
CO
Colombia
Prior art keywords
isoindolin
oxoethyl
piperidin
fluorophenyl
methyl
Prior art date
Application number
CONC2017/0005498A
Other languages
English (en)
Inventor
Remy Luthringer
Masahiro Okuyama
Nadine Noel
Sandra Werner
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CO2017005498A2 publication Critical patent/CO2017005498A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN La divulgación proporciona un nuevo polimorfo del Compuesto (I): monoclorhidrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona dihidratado, es decir, la Forma (A) del Compuesto (I)∙HCl∙2H2O. Se divulgan también composiciones farmacéuticas que comprenden la Forma (A) del Compuesto (I)∙HCl∙2H2O y métodos de tratamiento relacionados.
CONC2017/0005498A 2014-12-02 2017-05-31 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia CO2017005498A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29
PCT/US2015/062985 WO2016089766A1 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Publications (1)

Publication Number Publication Date
CO2017005498A2 true CO2017005498A2 (es) 2017-09-20

Family

ID=54848909

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005498A CO2017005498A2 (es) 2014-12-02 2017-05-31 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Country Status (26)

Country Link
US (6) US9458130B2 (es)
EP (2) EP4063357A1 (es)
JP (3) JP2018501217A (es)
KR (1) KR102620681B1 (es)
CN (2) CN111110677A (es)
AU (4) AU2015355226B2 (es)
BR (1) BR112017011555B1 (es)
CA (1) CA2968977A1 (es)
CL (2) CL2017001376A1 (es)
CO (1) CO2017005498A2 (es)
DK (1) DK3227273T3 (es)
EA (1) EA201791226A1 (es)
ES (1) ES2910528T3 (es)
HU (1) HUE058212T2 (es)
IL (3) IL301320A (es)
MX (1) MX2017007065A (es)
MY (1) MY185516A (es)
PE (1) PE20171646A1 (es)
PH (1) PH12017501007A1 (es)
PL (1) PL3227273T3 (es)
PT (1) PT3227273T (es)
SG (1) SG11201704332YA (es)
TW (1) TWI694069B (es)
UA (1) UA122780C2 (es)
WO (1) WO2016089766A1 (es)
ZA (1) ZA201703481B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089766A1 (en) * 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN109689055A (zh) * 2016-05-25 2019-04-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
IL271606B2 (en) * 2017-06-21 2024-05-01 Minerva Neurosciences Inc Stomach-resistant controlled-release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
US11083723B2 (en) * 2018-08-21 2021-08-10 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
EP3990113A1 (en) * 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
US20230255953A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
HUP0300203A3 (en) * 2000-02-29 2006-01-30 Mitsubishi Pharma Corp Novel cyclic amide derivatives, and pharmaceutical compositions containing same
WO2002076432A2 (en) 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
US7626056B2 (en) 2005-06-06 2009-12-01 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
TWI520949B (zh) * 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
CA2806017C (en) * 2010-07-20 2021-06-29 Cyrenaic Pharmaceuticals Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) * 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
WO2016089766A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN109689055A (zh) 2016-05-25 2019-04-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
IL271606B2 (en) 2017-06-21 2024-05-01 Minerva Neurosciences Inc Stomach-resistant controlled-release oral dosage forms
US11083723B2 (en) 2018-08-21 2021-08-10 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Also Published As

Publication number Publication date
US20230201184A1 (en) 2023-06-29
JP2018501217A (ja) 2018-01-18
WO2016089766A1 (en) 2016-06-09
AU2023258386A1 (en) 2023-11-23
NZ770365A (en) 2023-10-27
JP2020172531A (ja) 2020-10-22
AU2020204286A1 (en) 2020-07-16
BR112017011555A2 (pt) 2018-01-09
IL280052A (en) 2021-03-01
IL252347A0 (en) 2017-07-31
PE20171646A1 (es) 2017-11-13
TWI694069B (zh) 2020-05-21
US9458130B2 (en) 2016-10-04
MX2017007065A (es) 2017-12-18
AU2021229240B2 (en) 2023-08-24
AU2015355226B2 (en) 2020-04-02
EP3227273B1 (en) 2022-02-09
TW201632511A (zh) 2016-09-16
CL2021000044A1 (es) 2021-06-04
SG11201704332YA (en) 2017-06-29
US10799493B2 (en) 2020-10-13
PH12017501007A1 (en) 2017-12-18
IL252347B (en) 2021-01-31
DK3227273T3 (da) 2022-05-02
AU2020204286B2 (en) 2021-06-17
US20210228561A1 (en) 2021-07-29
NZ732033A (en) 2023-10-27
BR112017011555B1 (pt) 2023-10-03
EA201791226A1 (ru) 2017-09-29
US10258614B2 (en) 2019-04-16
KR20170106310A (ko) 2017-09-20
MY185516A (en) 2021-05-19
PT3227273T (pt) 2022-04-06
AU2015355226A1 (en) 2017-06-08
PL3227273T3 (pl) 2022-05-30
HUE058212T2 (hu) 2022-07-28
CL2017001376A1 (es) 2018-02-16
JP2022105159A (ja) 2022-07-12
KR102620681B1 (ko) 2024-01-04
CN107567444A (zh) 2018-01-09
JP7069253B2 (ja) 2022-05-17
US20160152597A1 (en) 2016-06-02
CA2968977A1 (en) 2016-06-09
US20170042877A1 (en) 2017-02-16
ES2910528T3 (es) 2022-05-12
CN111110677A (zh) 2020-05-08
IL301320A (en) 2023-05-01
IL280052B1 (en) 2023-05-01
ZA201703481B (en) 2023-12-20
US9730920B2 (en) 2017-08-15
EP3227273A1 (en) 2017-10-11
EP4063357A1 (en) 2022-09-28
US20200022968A1 (en) 2020-01-23
IL280052B2 (en) 2023-09-01
UA122780C2 (uk) 2021-01-06
US20180153871A1 (en) 2018-06-07
AU2021229240A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CL2021000044A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
ZA201701299B (en) Glycosidase inhibitors
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
IL246875A0 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
TW201613872A (en) IRAK4 inhibiting agents
UY36314A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6.
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
EA201791684A1 (ru) Селективные ингибиторы bace1
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MA44383A (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
EA201791596A1 (ru) Пиразоловые соединения
MA47193A (fr) Formes posologiques solides d'inhibiteurs bace1 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridine
PL407398A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-4-hydroksy-3-(4-metylobenzoilo)-2H-1,2-benzotiazyny o aktywności przeciwbólowej i przeciwzapalnej oraz sposób jego wytwarzania
PL407399A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-3-(4-fluorobenzoilo)-4-hydroksy-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania